RKDA — Stock Film
STOCK FILMSCENE 1/11RKDA · $0.46
Stock Expert AI presents
RKDA
Arcadia Biosciences, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Arcadia Biosciences, Inc. A quick introduction.

On the stock market since 2015, it operates in the world of raw materials. It has 8 employees. Now — the numbers.

on the stock market since 2015
8 employees
$1M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.5.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales have been shrinking.

An average decline of 8% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$6.8M
2021
$7.4M
2022
$4.5M
2023
$5M
2024
$4.9M
2025
In the vault right now:
$0
DEBT: $0
At this pace, that money lasts about 2 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
3 / 8
EXPECTATIONS MET OR BEATEN
3
Nov 2024
Mar 2025
May 2025
Aug 2025
Nov 2025
Mar 2026
May 2026
Aug 2026
3 TIMES IN THE LAST 8 QUARTERS
It misses the bar more often than not.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
5
very weak

Clearly below the class average.

FINANCIAL STRENGTH
41
weak

Clearly below the class average.

VALUATION
28
very weak

Clearly below the class average.

GROWTH
16
very weak

Clearly below the class average.

PRICE MOMENTUM
2
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Strong cash, light debt

There is $4.6M in the vault; even if every debt were paid off, $4.6M would remain.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 14 buys and 6 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $6.001,198% above today’s price.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $2.3M against $4.9M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
Trading under $1

The stock sits at $0.46. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts about 2 years. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, RKDA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: RKDA is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

Analysts’ average target sits above today’s price, yet the valuation grade (28/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film